NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CA-21-061 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-060 from the NIH Guide for Grants and Contracts
Notice NOT-DA-21-038 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-065 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-21-231 from the NIH Guide for Grants and Contracts. The NICHD Small Research Grant Program (Clinical Trial Required) supports clinical trials that fall within the NICHD mission. This funding opportunity announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required FOA.
Funding Opportunity PA-21-221 from the NIH Guide for Grants and Contracts. The NICHD Small Research Grant Program (Clinical Trial Required) supports clinical trials that fall within the NICHD mission.
Notice NOT-GM-21-045 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-21-012 from the NIH Guide for Grants and Contracts. Reissue of RFA-NS-19-011: The purpose of the NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award is to support a defined pathway across career stages for outstanding graduate students who are from backgrounds that are nationally underrepresented in neuroscience research. This two-phase award will facilitate completion of the doctoral dissertation and transition of talented graduate students to strong neuroscience research postdoctoral positions, and will provide career development opportunities relevant to their long-term career goal of becoming independent neuroscience researchers.
Notice NOT-AA-21-016 from the NIH Guide for Grants and Contracts
Notice NOT-AA-21-017 from the NIH Guide for Grants and Contracts
Notice NOT-AA-21-018 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-038 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-039 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-109 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-107 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-21-030 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support dynamic, multidisciplinary consortia of structural biologists, virologists, and computational scientists to resolve complex biological structures relevant to HIV prevention, treatment and cure. The consortia are expected to leverage common resources, facilitate new collaborations, and engage and train the next generation of HIV structural biology researchers.
Funding Opportunity PAR-21-209 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to recruit Early Stage Investigators (ESI) to pursue research programs of interest to NIH Chemical Countermeasures Research Program (CCRP) under the Countermeasures Against Chemical Threats (CounterACT) grant/cooperative agreement program. ESI CounterACT R21 projects may be exploratory, applied, proof of principle, or high risk-high impact research to discover safe and effective therapeutics to mitigate toxicities resulting from exposures to highly toxic chemicals. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including preliminary data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review. Projects supported by this FOA will have an extended level of support (3 years) and are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive funding support from the NIH CounterACT programs or other related initiatives.
Funding Opportunity RFA-HD-22-004 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support innovative, multidisciplinary, interactive, and synergistic program projects that integrate basic, translational, and clinical approaches to understanding the developmental biology and genetic basis of significant congenital human malformations. Each program project will consist of three component research projects, in addition to associated cores. At least one project must use basic research in an animal model system and at least one project must be clinical or translational in nature. The component research projects must share a common central theme, focus, or objective on a specific major developmental defect or malformation that is genotypically, mechanistically, biologically, or phenotypically analogous or homologous in both animal models and humans. Any non-mammalian or mammalian animal model may be used, as long as it contributes to the common overall theme or objective of the program project. The component research projects should share a common developmental gene, process, mechanism, pathway, or phenotype.
Notice NOT-HS-21-011 from the NIH Guide for Grants and Contracts
Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required)
Funding Opportunity RFA-MH-21-230 from the NIH Guide for Grants and Contracts. ADHD is a neurodevelopmental disorder with symptoms and impairments that emerge early and persist into adulthood for a substantial portion of affected individuals. While evidence-based treatments exist for school-age children and adolescents with ADHD, findings from longitudinal research suggests that children and adolescents who receive evidence-based interventions for ADHD remain significantly impaired relative to their non-ADHD peers over time. Early identification and intervention for young children with ADHD may be a necessary first step in normalizing symptoms across development and mitigating negative outcomes. The number of preschool children diagnosed with ADHD has been growing in recent years, more than doubling between 2007 and 2016 (Danielson et al., 2017). This increase may be due in part to the 2011 expansion of the American Academy of Pediatrics (AAP) ADHD Clinical Practice Guideline to include recommendations for children as young as 4-years-old (Wolraich et al., 2019). Behavioral interventions are recommended in the AAP Guideline as the first-line treatment for preschoolers with ADHD symptoms, due largely to parental preferences and data suggesting a higher rate of ADHD medication-related side effects and adverse events among younger children. Yet little research has been conducted to test the effectiveness of behavioral interventions in this population. A handful of completed NIMH-funded efficacy studies support the feasibility and promise of conducting interventions research in the preschool ADHD population. However, no preschool ADHD effectiveness trials designed to test service-ready, scalable approaches have been funded by NIMH to date, further highlighting the need for research in this area.